Avadel Pharmaceuticals (AVDL) Expected to Announce Earnings on Monday

Avadel Pharmaceuticals (NASDAQ:AVDL) is expected to be posting its quarterly earnings results before the market opens on Monday, March 3rd. Analysts expect Avadel Pharmaceuticals to post earnings of ($0.03) per share and revenue of $50.03 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Avadel Pharmaceuticals Price Performance

Avadel Pharmaceuticals stock opened at $7.91 on Friday. The stock’s 50 day moving average is $8.87 and its 200 day moving average is $11.71. Avadel Pharmaceuticals has a one year low of $7.39 and a one year high of $19.09. The firm has a market cap of $762.22 million, a P/E ratio of -10.01 and a beta of 1.28.

Analyst Ratings Changes

AVDL has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft began coverage on shares of Avadel Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price objective on the stock. Piper Sandler cut their price target on shares of Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. UBS Group decreased their price target on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating for the company in a report on Monday, January 13th. Needham & Company LLC dropped their price objective on Avadel Pharmaceuticals from $22.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, January 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $21.00 target price (down previously from $25.00) on shares of Avadel Pharmaceuticals in a research note on Friday, January 10th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $19.88.

Insider Activity

In other news, CEO Gregory J. Divis bought 9,598 shares of the stock in a transaction dated Friday, December 6th. The shares were bought at an average cost of $9.98 per share, with a total value of $95,788.04. Following the completion of the transaction, the chief executive officer now directly owns 9,598 shares of the company’s stock, valued at $95,788.04. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Linda Palczuk purchased 3,000 shares of Avadel Pharmaceuticals stock in a transaction that occurred on Friday, December 6th. The stock was acquired at an average cost of $10.19 per share, with a total value of $30,570.00. Following the transaction, the director now owns 66,400 shares in the company, valued at $676,616. This trade represents a 4.73 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 55,579 shares of company stock worth $526,363 in the last three months. Company insiders own 4.80% of the company’s stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.